Meanwhile, in vivo studies have further shown that the combination of PD-1 antibody treatment can significantly enhance the clearance of tumor cells from postoperative residual foci and lung metastases by tumor-specific CD8+ T cells, effectively inhibiting tumor recurrence and metastasis. This evidence concerns the gene CD8A and neoplasm.